Tags : International Congress 2020

AstraZeneca to Present Results of Breztri Aerosphere in P-III ETHOS

Shots: The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] with mod. to sev. COPD and a history of exacerbation(s) in the previous year A post-hoc analysis of the P-III ETHOS trial demonstrated a consistent benefit of Breztri Aerosphere in reducing the […]Read More